Invention Grant
- Patent Title: NY-ESO-1-containing artificial adjuvant vector cell for use in treatment of cancer
-
Application No.: US17781616Application Date: 2020-12-01
-
Publication No.: US11672851B2Publication Date: 2023-06-13
- Inventor: Ayaka Akiba , Tatsuya Okudaira , Yasuhide Masuhara , Keisuke Ohsumi , Shinichiro Fujii
- Applicant: ASTELLAS PHARMA INC. , RIKEN
- Applicant Address: JP Tokyo
- Assignee: RIKEN,ASTELLAS PHARMA INC.
- Current Assignee: RIKEN,ASTELLAS PHARMA INC.
- Current Assignee Address: JP Saitama; JP Tokyo
- Agency: Foley & Lardner LLP
- Priority: JP 2019217704 2019.12.02
- International Application: PCT/JP2020/044586 2020.12.01
- International Announcement: WO2021/112055A 2021.06.10
- Date entered country: 2022-06-01
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K14/74 ; C07K14/705 ; C12N5/10 ; C12N5/071 ; A61K35/00 ; A61P35/00 ; A61K45/06
Abstract:
An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.
Public/Granted literature
- US20230000965A1 NY-ESO-1-CONTAINING ARTIFICIAL ADJUVANT VECTOR CELL FOR USE IN TREATMENT OF CANCER Public/Granted day:2023-01-05
Information query
